fentanyl has been researched along with Chronic Disease in 151 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Transdermal fentanyl significantly improved visual analog scale scores and Oswestry Disability Index scores in 73% of patients, especially those with specific low back pain awaiting surgery; however, it did not decrease pain in 27% of patients, including patients with non-specific low back pain or multiple back operations." | 9.16 | Transdermal fentanyl for chronic low back pain. ( Aoki, Y; Arai, G; Eguchi, Y; Inoue, G; Ishikawa, T; Kamoda, H; Kishida, S; Kuniyoshi, K; Miyagi, M; Nakamura, J; Ochiai, N; Ohtori, S; Orita, S; Suzuki, M; Takahashi, K; Takaso, M; Toyone, T, 2012) |
| "This study assessed the long-term safety and tolerability of fentanyl buccal tablet (FBT) in opioid-tolerant patients with cancer and breakthrough pain (BTP) who were either naive to FBT or had completed 1 of 2 previous double-blind, placebo-controlled FBT studies (rollover patients)." | 9.14 | Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. ( Messina, J; Weinstein, SM; Xie, F, 2009) |
| "To evaluate the time of onset, overall efficacy, and safety of fentanyl buccal tablet (FBT) for noncancer-related breakthrough pain (BTP) in opioid-tolerant adults over 12 weeks." | 9.14 | A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. ( Farrar, JT; Messina, J; Portenoy, RK; Xie, F, 2010) |
| "This trial demonstrated that the lower 12 microg/h dose of fentanyl TTS provided a therapeutic benefit in non-malignant chronic pain, with a similar AE rate but a lower drop-out rate than that seen in trials at higher doses." | 9.12 | A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. ( Otis, J; Rothman, M, 2006) |
| "Fifty-six adults with chronic noncancer pain using oral transmucosal fentanyl citrate (OTFC, ACTIQ)." | 9.12 | Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). ( Chun, SY; Fortner, B; Reinking, J; Shoemaker, S; Stegman, M; Taylor, DR; Webster, LR, 2007) |
| "Sufentanil, a potent mu-opioid agonist, historically has not been been given systemically to treat chronic pain." | 9.11 | Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. ( Charapata, S; DuPen, S; Fisher, DM; Heinze, E; Katz, N; Portenoy, R; Rauck, R; Reynolds, L; Wallace, M; Webster, L, 2004) |
| "We treated 50 patients with chronic nonmalignant pain using transdermal fentanyl (TDF) 25 microg/hr and concurrently measured pain using a visual analog scale (VAS) and serum cortisol concentration." | 9.11 | The effect of transdermal fentanyl treatment on serum cortisol concentrations in patients with non-cancer pain. ( Altan, A; Ozyuvaci, E; Yanmaz Alnigenis, N, 2004) |
| "To compare the efficacy and safety of transdermal fentanyl (TDF) and sustained release morphine (SRM) in strong-opioid naïve patients with chronic low back pain (CLBP)." | 9.11 | Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. ( Allan, L; Richarz, U; Simpson, K; Slappendel, R, 2005) |
| "Chronic pain can be effectively treated with fentanyl-TTS, which has a very favorable side effect profile." | 9.11 | [Individual aspects of the quality of life of patients with chronic pain. Observational study of treatment with fentanyl-TTS]. ( Waap, I; Zimmermann, M, 2005) |
| "To compare patients' preference for transdermal fentanyl or sustained release oral morphine, their level of pain control, and their quality of life after treatment." | 9.09 | Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. ( Allan, L; Bolt, M; de Waroux, BL; Donald, R; Hays, H; Jensen, NH; Kalso, E, 2001) |
| "Patients were entered into an open label study to evaluate the efficacy of transdermal fentanyl as an analgesic for chronic cancer pain." | 9.07 | Transdermal fentanyl for chronic cancer pain: detailed case reports and the influence of confounding factors. ( Hogan, LA; Patt, RB, 1992) |
| "In this study, 11 cancer patients who experienced severe pain were treated with transdermal fentanyl." | 9.07 | Transdermal fentanyl use in hospice home-care patients with chronic cancer pain. ( Herbst, LH; Strause, LG, 1992) |
| "We performed a systematic review to evaluate the current evidence for the use of fentanyl for the relief of breathlessness." | 8.89 | Fentanyl for the relief of refractory breathlessness: a systematic review. ( Gaertner, J; Köskeroglu, P; Simon, ST; Voltz, R, 2013) |
| "Review key aspects of breakthrough pain management with fentanyl buccal tablet, with a focus on minimizing risk to optimize therapeutic outcomes." | 8.86 | Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. ( Fine, PG; Narayana, A; Passik, SD, 2010) |
| "Transdermal fentanyl patches first became available in the early 1990s and provided an innovative treatment for the management of cancer pain." | 8.85 | The role of transdermal fentanyl patches in the effective management of cancer pain. ( Gibbs, M, 2009) |
| "In the present study, we demonstrated that repeated treatment with fentanyl, but not morphine or oxycodone, causes a rapid desensitization to its ability to block the hyperalgesia associated with the attenuation of mu-opioid receptor resensitization in mice in a chronic pain-like state." | 8.84 | [Difference in tolerance to anti-hyperalgesic effect and its molecular mechanisms between chronic treatment with morphine, fentanyl and oxycodone in a chronic pain-like state]. ( Hashimoto, S; Kuzumaki, N; Nakamura, A; Narita, M; Ozeki, A; Satoshi, I; Suzuki, T; Uezono, Y, 2008) |
| "Transdermal fentanyl is effective and well tolerated for the treatment of chronic pain caused by malignancy and non-malignant conditions when administered according to the manufacturer's recommendations." | 8.82 | Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. ( Kornick, CA; Moryl, N; Obbens, EA; Payne, R; Santiago-Palma, J, 2003) |
| "To evaluate effectiveness and safety information of transdermal fentanyl (TDF) (Duragesic/Durogesic) and sustained-release oral morphine (SRM) in cancer pain (CP) and chronic non-cancer pain (NCP), a pooled analysis was conducted on datasets of published, open label, uncontrolled (no comparator group) and randomised controlled (with SRM as comparator) studies of TDF." | 8.82 | Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. ( Ahmedzai, SH; Allan, LG; Camacho, F; Clark, AJ; Horbay, GL; Richarz, U; Simpson, K, 2004) |
| "The physicochemical properties, pharmacology, pharmacokinetics, serum concentrations and clinical effects, adverse effects and contraindications, and dosage of transdermally administered fentanyl are described, and clinical studies evaluating the use of a transdermal fentanyl system in the treatment of postoperative pain and chronic cancer-associated pain are reviewed." | 8.78 | Transdermally administered fentanyl for pain management. ( Calis, KA; Corso, DM; Kohler, DR, 1992) |
| "This report describes an infant who was born to a mother with chronic pain treated with fentanyl 100 microg/h transdermal patch throughout her pregnancy and during lactation." | 7.75 | Fentanyl transdermal analgesia during pregnancy and lactation. ( Cohen, RS, 2009) |
| "Given preemptively, nefopam may be effective at improving postoperative pain management and at reducing the risk of developing postoperative chronic pain, because the drug has both analgesic and antihyperalgesic properties." | 7.75 | Long-term pain vulnerability after surgery in rats: prevention by nefopam, an analgesic with antihyperalgesic properties. ( Chateauraynaud, J; Laboureyras, E; Richebé, P; Simonnet, G, 2009) |
| "This retrospective study identified patients with cancer and noncancer pain who had received > or =1 prescription for fentanyl TD or buprenorphine TD (the all-patients groups) from the German IMS Disease Analyzer-mediplus database, which contains all relevant data concerning drug prescriptions from 400 practices in Germany." | 7.73 | Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. ( Likar, R; Nautrup, BP; Sittl, R, 2005) |
| "The analgesic effect of long-acting opioids, such as transdermal fentanyl, has been demonstrated in patients with cancer, neuropathic pain and chronic low back pain (CLBP)." | 7.73 | An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system. ( Ascher, S; Frank, L; Harte, C; Kosinski, MR; Margolis, MK; Schein, JR; Shikiar, R; Vallow, SM; Vorsanger, G, 2005) |
| "To evaluate driving performance, cognition, and balance in patients with chronic nonmalignant pain before and after the addition of transdermal fentanyl to their treatments." | 7.72 | The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. ( Besser, M; Crerand, C; Frank, ED; Jalali, S; Menefee, LA; Park, J; Sanschagrin, K, 2004) |
| "To assess the analgesic safety and efficacy of Transdermal Therapeutic System (TTS)-fentanyl in the treatment of chronic gynecological cancer-related pain." | 7.72 | Evaluation of safety and efficacy of transdermal therapeutic system-fentanyl in adult patients with gynecological cancer-related pain. ( Cheewakriangkrai, C; Katanyoo, K; Lorvidhaya, V; Srisomboon, J; Suprapaphorn, P, 2004) |
| "This prospective, open-label, before-after trial was designed to compare the efficacy of oral opioids with that of transdermal fentanyl in severe AIDS-related chronic pain, as well as assess barriers, patient satisfaction, and side effects." | 7.71 | Transdermal fentanyl for chronic pain in AIDS: a pilot study. ( Lefkowitz, M; Newshan, G, 2001) |
| "The fentanyl transdermal system (Duragesic) is an opioid analgesic indicated for the management of chronic moderate to severe pain." | 7.71 | Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. ( Bell, TJ; Dodd, SL; Neighbors, DM; Wilson, J, 2001) |
| "A transdermal fentanyl patch for the treatment of chronic cancer-related pain is available in four dosages (25, 50, 75, and 100 microg/hr)." | 7.70 | Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. ( Payne, R, 1998) |
| "To report a case of high transdermal fentanyl dosage requirements in a patient with chronic cancer pain." | 7.68 | High transdermal fentanyl requirements in a patient with chronic cancer pain. ( Lehr, VT; Renaud, EA, 1993) |
| "Five cancer patients experienced satisfactory pain relief for periods of 3-156 days using continuous transdermal delivery of the narcotic fentanyl." | 7.67 | Transdermal fentanyl for pain control in patients with cancer. ( Dothage, JA; Miser, AW; Miser, JS; Narang, PK; Sindelar, W; Young, RC, 1989) |
| "To investigate the selective role of intraspinal opioids on the perception and modulation of pain, seven subjects with chronic hip or back pain and one subject with C-6 quadriplegia received 25 micrograms of intrathecal fentanyl." | 7.67 | Intrathecal fentanyl depresses nociceptive flexion reflexes in patients with chronic pain. ( Chabal, C; Jacobson, L; Little, J, 1989) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 6.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| " Adverse events were also recorded." | 6.76 | The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. ( Ashburn, MA; Messina, J; Slevin, KA; Xie, F, 2011) |
| "During maintenance treatment, 70 of 646 patients (11%) discontinued because of adverse events (AEs), 69 of 646 (11%) because of withdrawn consent, and 57 of 646 (9%) because of noncompliance." | 6.75 | Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. ( Fine, PG; Messina, J; Rathmell, J; Xie, F, 2010) |
| " Pain intensity (PI) (rated on an 11-point pain scale, from 0 = no pain to 10 = worst pain) and other outcomes were assessed before dosing and for 2 hours after dosing." | 6.73 | Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. ( Hale, M; Messina, J; Simpson, DM; Xie, F, 2007) |
| " Large patient-to-patient variations in pharmacokinetic parameters occurred, although intraindividual variability was limited." | 6.71 | Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ( Bressolle, F; Caumette, L; Culine, S; Garcia, F; Pinguet, F; Poujol, S; Solassol, I, 2005) |
| "TTS fentanyl was titrated to pain relief, and patients were followed up for as long as 3 months." | 6.69 | A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. ( Hays, H; Moulin, DE; Sloan, PA, 1998) |
| "Fentanyl is an opioid initially developed for parenteral administration." | 5.36 | Formulations of fentanyl for the management of pain. ( Grape, S; Lauer, S; Schug, BS; Schug, SA, 2010) |
| "Fentanyl patch is an alternative for children who cannot tolerate morphine." | 5.35 | Fentanyl patch for stable chronic pain in children: new indication. Used fentanyl patches should be handled with care. ( , 2008) |
| "Morphine side effects were reduced in some patients who changed to transdermal fentanyl, but there was no reduction in those who needed high-dose morphine for rescue analgesia." | 5.32 | A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center. ( Hasegawa, M; Hosoda, R; Kamiya, Y; Kato, K; Mizaki, T; Nitta, M; Yamazaki, S, 2004) |
| "Transdermal fentanyl significantly improved visual analog scale scores and Oswestry Disability Index scores in 73% of patients, especially those with specific low back pain awaiting surgery; however, it did not decrease pain in 27% of patients, including patients with non-specific low back pain or multiple back operations." | 5.16 | Transdermal fentanyl for chronic low back pain. ( Aoki, Y; Arai, G; Eguchi, Y; Inoue, G; Ishikawa, T; Kamoda, H; Kishida, S; Kuniyoshi, K; Miyagi, M; Nakamura, J; Ochiai, N; Ohtori, S; Orita, S; Suzuki, M; Takahashi, K; Takaso, M; Toyone, T, 2012) |
| "This study assessed the long-term safety and tolerability of fentanyl buccal tablet (FBT) in opioid-tolerant patients with cancer and breakthrough pain (BTP) who were either naive to FBT or had completed 1 of 2 previous double-blind, placebo-controlled FBT studies (rollover patients)." | 5.14 | Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. ( Messina, J; Weinstein, SM; Xie, F, 2009) |
| "To evaluate the time of onset, overall efficacy, and safety of fentanyl buccal tablet (FBT) for noncancer-related breakthrough pain (BTP) in opioid-tolerant adults over 12 weeks." | 5.14 | A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. ( Farrar, JT; Messina, J; Portenoy, RK; Xie, F, 2010) |
| "This study aimed to (1) evaluate the psychometric properties of PAC-SYM in assessing the symptoms and severity of opioid-induced constipation; (2) test for differences in opioid-induced constipation between Durogesic fentanyl transdermal reservoir (TDF) and oral sustained-release morphine (SRM) in patients with chronic low back pain (CLBP)." | 5.12 | Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. ( Dubois, D; Keininger, DL; Simpson, K; Slappendel, R, 2006) |
| "This trial demonstrated that the lower 12 microg/h dose of fentanyl TTS provided a therapeutic benefit in non-malignant chronic pain, with a similar AE rate but a lower drop-out rate than that seen in trials at higher doses." | 5.12 | A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. ( Otis, J; Rothman, M, 2006) |
| "Fifty-six adults with chronic noncancer pain using oral transmucosal fentanyl citrate (OTFC, ACTIQ)." | 5.12 | Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). ( Chun, SY; Fortner, B; Reinking, J; Shoemaker, S; Stegman, M; Taylor, DR; Webster, LR, 2007) |
| "Sufentanil, a potent mu-opioid agonist, historically has not been been given systemically to treat chronic pain." | 5.11 | Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. ( Charapata, S; DuPen, S; Fisher, DM; Heinze, E; Katz, N; Portenoy, R; Rauck, R; Reynolds, L; Wallace, M; Webster, L, 2004) |
| "We treated 50 patients with chronic nonmalignant pain using transdermal fentanyl (TDF) 25 microg/hr and concurrently measured pain using a visual analog scale (VAS) and serum cortisol concentration." | 5.11 | The effect of transdermal fentanyl treatment on serum cortisol concentrations in patients with non-cancer pain. ( Altan, A; Ozyuvaci, E; Yanmaz Alnigenis, N, 2004) |
| "A study of the urinary concentration of fentanyl (F) and its major metabolite norfentanyl (NF) in chronic pain patients treated with the Duragesic continuous release transdermal patches is presented." | 5.11 | Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches. ( Backer, R; Poklis, A, 2004) |
| "To compare the efficacy and safety of transdermal fentanyl (TDF) and sustained release morphine (SRM) in strong-opioid naïve patients with chronic low back pain (CLBP)." | 5.11 | Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. ( Allan, L; Richarz, U; Simpson, K; Slappendel, R, 2005) |
| "Chronic pain can be effectively treated with fentanyl-TTS, which has a very favorable side effect profile." | 5.11 | [Individual aspects of the quality of life of patients with chronic pain. Observational study of treatment with fentanyl-TTS]. ( Waap, I; Zimmermann, M, 2005) |
| "To evaluate transdermal fentanyl plaster versus sustained release morphine tablets as analgesic treatment of painful chronic pancreatitis." | 5.09 | Opioid treatment of painful chronic pancreatitis. ( Larsen, S; Madsen, LG; Niemann, T; Thorsgaard, N, 2000) |
| "To compare patients' preference for transdermal fentanyl or sustained release oral morphine, their level of pain control, and their quality of life after treatment." | 5.09 | Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. ( Allan, L; Bolt, M; de Waroux, BL; Donald, R; Hays, H; Jensen, NH; Kalso, E, 2001) |
| "Patients were entered into an open label study to evaluate the efficacy of transdermal fentanyl as an analgesic for chronic cancer pain." | 5.07 | Transdermal fentanyl for chronic cancer pain: detailed case reports and the influence of confounding factors. ( Hogan, LA; Patt, RB, 1992) |
| "In this study, 11 cancer patients who experienced severe pain were treated with transdermal fentanyl." | 5.07 | Transdermal fentanyl use in hospice home-care patients with chronic cancer pain. ( Herbst, LH; Strause, LG, 1992) |
| "We performed a systematic review to evaluate the current evidence for the use of fentanyl for the relief of breathlessness." | 4.89 | Fentanyl for the relief of refractory breathlessness: a systematic review. ( Gaertner, J; Köskeroglu, P; Simon, ST; Voltz, R, 2013) |
| "Fentanyl is a potent opioid analgesic marketed for the treatment of stable intense chronic pain, particularly in the form of a transdermal patch." | 4.86 | Fentanyl patches: preventable overdose. ( , 2010) |
| "Review key aspects of breakthrough pain management with fentanyl buccal tablet, with a focus on minimizing risk to optimize therapeutic outcomes." | 4.86 | Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. ( Fine, PG; Narayana, A; Passik, SD, 2010) |
| "Transdermal fentanyl patches first became available in the early 1990s and provided an innovative treatment for the management of cancer pain." | 4.85 | The role of transdermal fentanyl patches in the effective management of cancer pain. ( Gibbs, M, 2009) |
| "To evaluate the underlying pharmacology, safety, and misuse/abuse of transdermal fentanyl, one of the cornerstone pharmacotherapies for patients with chronic pain." | 4.85 | Transdermal fentanyl: pharmacology and toxicology. ( Nelson, L; Schwaner, R, 2009) |
| "In the present study, we demonstrated that repeated treatment with fentanyl, but not morphine or oxycodone, causes a rapid desensitization to its ability to block the hyperalgesia associated with the attenuation of mu-opioid receptor resensitization in mice in a chronic pain-like state." | 4.84 | [Difference in tolerance to anti-hyperalgesic effect and its molecular mechanisms between chronic treatment with morphine, fentanyl and oxycodone in a chronic pain-like state]. ( Hashimoto, S; Kuzumaki, N; Nakamura, A; Narita, M; Ozeki, A; Satoshi, I; Suzuki, T; Uezono, Y, 2008) |
| "Transdermal fentanyl is effective and well tolerated for the treatment of chronic pain caused by malignancy and non-malignant conditions when administered according to the manufacturer's recommendations." | 4.82 | Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. ( Kornick, CA; Moryl, N; Obbens, EA; Payne, R; Santiago-Palma, J, 2003) |
| "To evaluate effectiveness and safety information of transdermal fentanyl (TDF) (Duragesic/Durogesic) and sustained-release oral morphine (SRM) in cancer pain (CP) and chronic non-cancer pain (NCP), a pooled analysis was conducted on datasets of published, open label, uncontrolled (no comparator group) and randomised controlled (with SRM as comparator) studies of TDF." | 4.82 | Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. ( Ahmedzai, SH; Allan, LG; Camacho, F; Clark, AJ; Horbay, GL; Richarz, U; Simpson, K, 2004) |
| "In this article, three aspects of recent issues in cancer pain management such as pain assessment, drowsiness with morphine, and problem in home care setting." | 4.81 | [Issues in cancer pain management]. ( Hoka, S; Matoba, M; Murakami, S, 2001) |
| "To review the use of transdermal fentanyl for the treatment of moderate to severe chronic pain." | 4.78 | Transdermal fentanyl. ( Lopez, JR; Yee, LY, 1992) |
| "The physicochemical properties, pharmacology, pharmacokinetics, serum concentrations and clinical effects, adverse effects and contraindications, and dosage of transdermally administered fentanyl are described, and clinical studies evaluating the use of a transdermal fentanyl system in the treatment of postoperative pain and chronic cancer-associated pain are reviewed." | 4.78 | Transdermally administered fentanyl for pain management. ( Calis, KA; Corso, DM; Kohler, DR, 1992) |
| "This report describes an infant who was born to a mother with chronic pain treated with fentanyl 100 microg/h transdermal patch throughout her pregnancy and during lactation." | 3.75 | Fentanyl transdermal analgesia during pregnancy and lactation. ( Cohen, RS, 2009) |
| "Given preemptively, nefopam may be effective at improving postoperative pain management and at reducing the risk of developing postoperative chronic pain, because the drug has both analgesic and antihyperalgesic properties." | 3.75 | Long-term pain vulnerability after surgery in rats: prevention by nefopam, an analgesic with antihyperalgesic properties. ( Chateauraynaud, J; Laboureyras, E; Richebé, P; Simonnet, G, 2009) |
| "This retrospective study identified patients with cancer and noncancer pain who had received > or =1 prescription for fentanyl TD or buprenorphine TD (the all-patients groups) from the German IMS Disease Analyzer-mediplus database, which contains all relevant data concerning drug prescriptions from 400 practices in Germany." | 3.73 | Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. ( Likar, R; Nautrup, BP; Sittl, R, 2005) |
| "The analgesic effect of long-acting opioids, such as transdermal fentanyl, has been demonstrated in patients with cancer, neuropathic pain and chronic low back pain (CLBP)." | 3.73 | An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system. ( Ascher, S; Frank, L; Harte, C; Kosinski, MR; Margolis, MK; Schein, JR; Shikiar, R; Vallow, SM; Vorsanger, G, 2005) |
| "The use of fentanyl patches has become accepted as standard in Germany for the treatment of chronic and cancer pain." | 3.73 | [Medico-legal aspects of the use of fentanyl patches]. ( Zimmermann, M, 2006) |
| "To evaluate driving performance, cognition, and balance in patients with chronic nonmalignant pain before and after the addition of transdermal fentanyl to their treatments." | 3.72 | The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. ( Besser, M; Crerand, C; Frank, ED; Jalali, S; Menefee, LA; Park, J; Sanschagrin, K, 2004) |
| "To assess the analgesic safety and efficacy of Transdermal Therapeutic System (TTS)-fentanyl in the treatment of chronic gynecological cancer-related pain." | 3.72 | Evaluation of safety and efficacy of transdermal therapeutic system-fentanyl in adult patients with gynecological cancer-related pain. ( Cheewakriangkrai, C; Katanyoo, K; Lorvidhaya, V; Srisomboon, J; Suprapaphorn, P, 2004) |
| "Transdermal fentanyl is an opioid analgesic that is effective on chronic pain, and which appears to be advantageous due to several factors such as ease of administration, the relatively stable serum concentration and long dose intervals." | 3.72 | Oral transmucosal abuse of transdermal fentanyl. ( Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Mellos, E; Rabavilas, AD, 2004) |
| "This prospective, open-label, before-after trial was designed to compare the efficacy of oral opioids with that of transdermal fentanyl in severe AIDS-related chronic pain, as well as assess barriers, patient satisfaction, and side effects." | 3.71 | Transdermal fentanyl for chronic pain in AIDS: a pilot study. ( Lefkowitz, M; Newshan, G, 2001) |
| "The fentanyl transdermal system (Duragesic) is an opioid analgesic indicated for the management of chronic moderate to severe pain." | 3.71 | Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. ( Bell, TJ; Dodd, SL; Neighbors, DM; Wilson, J, 2001) |
| "The study examined the validity of oral fentanyl self-administration (FSA) as a measure of the chronic nociceptive pain that develops in rats with adjuvant arthritis independently of acute noxious challenges." | 3.71 | Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats. ( Alliaga, M; Attal, N; Bruins Slot, LA; Colpaert, FC; Koek, W; Tarayre, JP, 2001) |
| "A transdermal fentanyl patch for the treatment of chronic cancer-related pain is available in four dosages (25, 50, 75, and 100 microg/hr)." | 3.70 | Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. ( Payne, R, 1998) |
| " The current report details five children in whom a percutaneously placed lumbar intrathecal catheter was used: (i) to provide intraoperative surgical anaesthesia instead of general anaesthesia (ii); to deliver intrathecal fentanyl to provide postoperative analgesia (iii); to provide chronic pain control during the terminal stages of metastatic malignancy; (iv) to allow repeated doses of intrathecal chemotherapy; and (v) to allow CSF drainage and prevent CSF leakage following frontal encephalocele repair." | 3.70 | Applications of intrathecal catheters in children. ( Tobias, JD, 2000) |
| "To report a case of high transdermal fentanyl dosage requirements in a patient with chronic cancer pain." | 3.68 | High transdermal fentanyl requirements in a patient with chronic cancer pain. ( Lehr, VT; Renaud, EA, 1993) |
| "Diagnostic epidural blocks were performed on 27 chronic pain patients sequentially using saline, fentanyl, and lidocaine solution." | 3.67 | Diagnostic epidural opioid technique. ( Ellis, JS; Hoffman, J; Ramamurthy, S; Schoenfeld, LS; Walsh, NE, 1989) |
| "Five cancer patients experienced satisfactory pain relief for periods of 3-156 days using continuous transdermal delivery of the narcotic fentanyl." | 3.67 | Transdermal fentanyl for pain control in patients with cancer. ( Dothage, JA; Miser, AW; Miser, JS; Narang, PK; Sindelar, W; Young, RC, 1989) |
| "To investigate the selective role of intraspinal opioids on the perception and modulation of pain, seven subjects with chronic hip or back pain and one subject with C-6 quadriplegia received 25 micrograms of intrathecal fentanyl." | 3.67 | Intrathecal fentanyl depresses nociceptive flexion reflexes in patients with chronic pain. ( Chabal, C; Jacobson, L; Little, J, 1989) |
| "The investigation of gas exchange, central hemodynamics and real oxygen transport has shown expediency of using ether and fluothane as main anesthetic drugs in operations on the lungs in patients with a compensated form of chronic pulmonary respiratory insufficiency." | 3.67 | [Clinico-physiological substantiation of using various methods of anesthesia in operations on the lungs in patients with chronic respiratory insufficiency]. ( Zverev, VV, 1985) |
| " Various retrospective studies comparing dosage changes of buprenorphine and fentanyl patches in persistent pain patients have been completed; however, no long-term prospective, randomized, clinical study has compared the effectiveness of these patches." | 2.78 | A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. ( Chowdhury, S; Mitra, F; Shelley, M; Williams, G, 2013) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 2.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| " Adverse events were also recorded." | 2.76 | The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. ( Ashburn, MA; Messina, J; Slevin, KA; Xie, F, 2011) |
| "During maintenance treatment, 70 of 646 patients (11%) discontinued because of adverse events (AEs), 69 of 646 (11%) because of withdrawn consent, and 57 of 646 (9%) because of noncompliance." | 2.75 | Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. ( Fine, PG; Messina, J; Rathmell, J; Xie, F, 2010) |
| " The dosage used was 50% of that indicated in equipotency conversion tables." | 2.74 | Opioids switching with transdermal systems in chronic cancer pain. ( Aurilio, C; Barbarisi, M; Grella, E; Pace, MC; Passavanti, MB; Pota, V; Sansone, P, 2009) |
| " Pain intensity (PI) (rated on an 11-point pain scale, from 0 = no pain to 10 = worst pain) and other outcomes were assessed before dosing and for 2 hours after dosing." | 2.73 | Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. ( Hale, M; Messina, J; Simpson, DM; Xie, F, 2007) |
| " Large patient-to-patient variations in pharmacokinetic parameters occurred, although intraindividual variability was limited." | 2.71 | Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ( Bressolle, F; Caumette, L; Culine, S; Garcia, F; Pinguet, F; Poujol, S; Solassol, I, 2005) |
| " Transdermal fentanyl dosage was titrated upwards as required." | 2.70 | Opioids in non-cancer pain: a life-time sentence? ( Dellemijn, PL, 2001) |
| "TTS fentanyl was titrated to pain relief, and patients were followed up for as long as 3 months." | 2.69 | A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. ( Hays, H; Moulin, DE; Sloan, PA, 1998) |
| "Pain is a multidimensional symptom that can overshadow all other experiences of both the child and family." | 2.44 | The management of pain in children with life-limiting illnesses. ( Friedrichsdorf, SJ; Kang, TI, 2007) |
| "Studies of populations with chronic cancer pain have shown a high prevalence of breakthrough pain (BTP), defined as transitory, severe flares of pain that occur on a background of otherwise controlled, persistent pain." | 2.44 | Fentanyl buccal tablet. ( Darwish, M; Fine, PG; Messina, J, 2008) |
| " Regular pain assessments combined with appropriate analgesic administration at regular dosing intervals, adjunctive drug therapy for control of adverse effects and associated symptoms, and nonpharmacological interventions are recommended." | 2.42 | Cancer pain management in children. ( Mercadante, S, 2004) |
| " Latency is a much less important problem for chronic administration in cancer pain." | 2.39 | [Transcutaneous fentanyl]. ( Estève, M, 1994) |
| "Fentanyl is an opioid initially developed for parenteral administration." | 1.36 | Formulations of fentanyl for the management of pain. ( Grape, S; Lauer, S; Schug, BS; Schug, SA, 2010) |
| " We show that the opioid Fentanyl, and its structurally similar sedative Zolpidem, can be embedded into metakaolin based geopolymer pellets to provide prolonged release dosage forms with mechanical strengths of the same order of magnitude as that of human teeth." | 1.36 | Mechanically strong geopolymers offer new possibilities in treatment of chronic pain. ( Bredenberg, S; Engqvist, H; Forsgren, J; Jämstorp, E; Strømme, M, 2010) |
| "Fentanyl patch is an alternative for children who cannot tolerate morphine." | 1.35 | Fentanyl patch for stable chronic pain in children: new indication. Used fentanyl patches should be handled with care. ( , 2008) |
| "Morphine side effects were reduced in some patients who changed to transdermal fentanyl, but there was no reduction in those who needed high-dose morphine for rescue analgesia." | 1.32 | A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center. ( Hasegawa, M; Hosoda, R; Kamiya, Y; Kato, K; Mizaki, T; Nitta, M; Yamazaki, S, 2004) |
| "Fentanyl has a 7 gram usage versus a 100 gram INCB allocation." | 1.31 | Opioid use in chronic pain management in the Philippines. ( Espinosa, EL; Harder, SM; Javier, FO; Magpantay, LA; Unite, MA, 2001) |
| "Fentanyl and midazolam is a combination that is effective and convenient to use because both agents are relatively short acting, have little cardiovascular depression and are easily reversible (with naloxone and flumazenil)." | 1.29 | Analgesia and sedation in interventional radiological procedures. ( Hart, GK; Hennessy, OF; Hiew, CY; Thomson, KR, 1995) |
| "The patients included 14 intravenous drug abusers, five of whom were on methadone maintenance." | 1.29 | Evaluation of recalcitrant pain in HIV-infected hospitalized patients. ( Anand, A; Carmosino, L; Glatt, AE, 1994) |
| " Recommendations for managing opioid-induced muscle hyperactivity include reduction of the opioid dosage and/or administration of clonazepam therapy." | 1.29 | Opioid-induced muscle activity: implications for managing chronic pain. ( Levitt, R; Steen, PD; Sylvester, RK, 1995) |
| "However in the acute postoperative pain group other factors such as depletion of endorphins by drugs used for anesthesia or due to surgical stress cannot be excluded." | 1.26 | [Measurement of endorphins in human cerebrospinal fluid. Comparative study of various groups of patients]. ( Laorden, ML; Miralles, F; Olaso, MJ; Puig, MM, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (6.62) | 18.7374 |
| 1990's | 34 (22.52) | 18.2507 |
| 2000's | 85 (56.29) | 29.6817 |
| 2010's | 21 (13.91) | 24.3611 |
| 2020's | 1 (0.66) | 2.80 |
| Authors | Studies |
|---|---|
| Shim, JS | 1 |
| Song, WJ | 1 |
| Morice, AH | 1 |
| Jassar, H | 1 |
| Nascimento, TD | 1 |
| Kaciroti, N | 1 |
| DosSantos, MF | 1 |
| Danciu, T | 1 |
| Koeppe, RA | 1 |
| Smith, YR | 1 |
| Bigal, ME | 1 |
| Porreca, F | 1 |
| Casey, KL | 1 |
| Zubieta, JK | 3 |
| DaSilva, AF | 1 |
| Simon, ST | 1 |
| Köskeroglu, P | 1 |
| Gaertner, J | 1 |
| Voltz, R | 1 |
| Martikainen, IK | 2 |
| Peciña, M | 2 |
| Love, TM | 2 |
| Nuechterlein, EB | 2 |
| Cummiford, CM | 2 |
| Green, CR | 2 |
| Harris, RE | 1 |
| Stohler, CS | 2 |
| Domingo-Triadó, V | 1 |
| López Alarcón, MD | 1 |
| Villegas Estévez, F | 1 |
| Alba Moratillas, C | 1 |
| Massa Domínguez, B | 1 |
| Palomares Payá, F | 1 |
| Mínguez Martí, A | 1 |
| Debón Vicent, L | 1 |
| Gross, DP | 1 |
| Bhambhani, Y | 1 |
| Haykowsky, MJ | 1 |
| Rashiq, S | 2 |
| Fishbain, DA | 1 |
| Hair, PI | 1 |
| Keating, GM | 1 |
| McKeage, K | 1 |
| Nolte, T | 2 |
| Oztürk, T | 1 |
| Karadibak, K | 1 |
| Catal, D | 1 |
| Cakan, A | 1 |
| Tugsavul, F | 1 |
| Cirak, K | 1 |
| Satoshi, I | 1 |
| Narita, M | 2 |
| Ozeki, A | 1 |
| Nakamura, A | 1 |
| Hashimoto, S | 1 |
| Kuzumaki, N | 1 |
| Uezono, Y | 1 |
| Suzuki, T | 1 |
| Cohen, RS | 1 |
| Weinstein, SM | 1 |
| Messina, J | 7 |
| Xie, F | 6 |
| Aurilio, C | 1 |
| Pace, MC | 1 |
| Pota, V | 1 |
| Sansone, P | 1 |
| Barbarisi, M | 1 |
| Grella, E | 1 |
| Passavanti, MB | 1 |
| Laboureyras, E | 1 |
| Chateauraynaud, J | 1 |
| Richebé, P | 1 |
| Simonnet, G | 1 |
| Gibbs, M | 1 |
| Grewal, PK | 1 |
| Firnhaber-Burgos, JB | 1 |
| Nelson, L | 1 |
| Schwaner, R | 1 |
| Grape, S | 1 |
| Schug, SA | 1 |
| Lauer, S | 1 |
| Schug, BS | 1 |
| Van Nimmen, NF | 1 |
| Poels, KL | 1 |
| Menten, JJ | 1 |
| Godderis, L | 1 |
| Veulemans, HA | 1 |
| Nomura, M | 1 |
| Kamata, M | 1 |
| Kojima, H | 1 |
| Hayashi, K | 1 |
| Kozai, M | 1 |
| Sawada, S | 1 |
| Fine, PG | 4 |
| Rathmell, J | 1 |
| Kahner-Gröne, S | 1 |
| Agternkamp, C | 1 |
| Freundl, D | 1 |
| Jersch, B | 1 |
| Heller, R | 1 |
| Palissa, H | 1 |
| Narayana, A | 1 |
| Passik, SD | 1 |
| Jämstorp, E | 1 |
| Forsgren, J | 1 |
| Bredenberg, S | 1 |
| Engqvist, H | 1 |
| Strømme, M | 1 |
| Farrar, JT | 1 |
| Portenoy, RK | 2 |
| Park, JH | 1 |
| Kim, JH | 1 |
| Yun, SC | 1 |
| Roh, SW | 1 |
| Rhim, SC | 1 |
| Kim, CJ | 1 |
| Jeon, SR | 1 |
| Williams, BS | 1 |
| Wong, D | 1 |
| Amin, S | 1 |
| Ashburn, MA | 1 |
| Slevin, KA | 1 |
| Loeser, B | 1 |
| Zöllner, C | 1 |
| Tramullas, M | 1 |
| Dinan, TG | 1 |
| Cryan, JF | 1 |
| Ohtori, S | 1 |
| Inoue, G | 1 |
| Orita, S | 1 |
| Eguchi, Y | 1 |
| Ochiai, N | 1 |
| Kishida, S | 1 |
| Takaso, M | 1 |
| Aoki, Y | 1 |
| Kuniyoshi, K | 1 |
| Nakamura, J | 1 |
| Ishikawa, T | 1 |
| Arai, G | 1 |
| Miyagi, M | 1 |
| Kamoda, H | 1 |
| Suzuki, M | 1 |
| Toyone, T | 1 |
| Takahashi, K | 1 |
| Mitra, F | 1 |
| Chowdhury, S | 1 |
| Shelley, M | 1 |
| Williams, G | 1 |
| Persoli-Gudelj, M | 1 |
| Babić-Naglić, D | 1 |
| Jajić, Z | 1 |
| Gnjidić, Z | 1 |
| Stambuk, B | 1 |
| Ross, JR | 1 |
| Quigley, C | 1 |
| Oefelein, MG | 1 |
| Bayazit, Y | 1 |
| Koller, M | 1 |
| Haykowsky, M | 1 |
| Jamieson, K | 1 |
| Kornick, CA | 1 |
| Santiago-Palma, J | 1 |
| Moryl, N | 1 |
| Payne, R | 2 |
| Obbens, EA | 1 |
| Tennant, F | 1 |
| Hermann, L | 1 |
| Menefee, LA | 1 |
| Frank, ED | 1 |
| Crerand, C | 1 |
| Jalali, S | 1 |
| Park, J | 1 |
| Sanschagrin, K | 1 |
| Besser, M | 1 |
| Lorvidhaya, V | 1 |
| Katanyoo, K | 1 |
| Srisomboon, J | 1 |
| Suprapaphorn, P | 1 |
| Cheewakriangkrai, C | 1 |
| Kato, K | 1 |
| Mizaki, T | 1 |
| Yamazaki, S | 1 |
| Nitta, M | 1 |
| Hasegawa, M | 1 |
| Kamiya, Y | 1 |
| Hosoda, R | 1 |
| White, SM | 1 |
| Hunt, T | 1 |
| Liappas, IA | 1 |
| Dimopoulos, NP | 1 |
| Mellos, E | 1 |
| Gitsa, OE | 1 |
| Liappas, AI | 1 |
| Rabavilas, AD | 1 |
| Reynolds, L | 1 |
| Rauck, R | 1 |
| Webster, L | 1 |
| DuPen, S | 1 |
| Heinze, E | 1 |
| Portenoy, R | 1 |
| Katz, N | 1 |
| Charapata, S | 1 |
| Wallace, M | 1 |
| Fisher, DM | 1 |
| Ozyuvaci, E | 1 |
| Yanmaz Alnigenis, N | 1 |
| Altan, A | 1 |
| Clark, AJ | 1 |
| Ahmedzai, SH | 1 |
| Allan, LG | 1 |
| Camacho, F | 1 |
| Horbay, GL | 1 |
| Richarz, U | 2 |
| Simpson, K | 3 |
| Figurska, M | 1 |
| Płocnarska, E | 1 |
| Stankiewicz, A | 1 |
| Rybicki, Z | 1 |
| Rekas, M | 1 |
| Poklis, A | 1 |
| Backer, R | 1 |
| Mercadante, S | 1 |
| Riem, L | 1 |
| Sivaci, R | 1 |
| Yilmaz, MD | 1 |
| Balci, C | 1 |
| Erincler, T | 1 |
| Unlu, H | 1 |
| Akkaya, T | 1 |
| Sayin, M | 1 |
| Gümüş, H | 1 |
| Sittl, R | 1 |
| Likar, R | 1 |
| Nautrup, BP | 1 |
| Saunders, P | 1 |
| Gannon, R | 1 |
| Slappendel, R | 2 |
| Dubois, D | 1 |
| Keininger, DL | 1 |
| Kosinski, MR | 1 |
| Schein, JR | 1 |
| Vallow, SM | 1 |
| Ascher, S | 1 |
| Harte, C | 1 |
| Shikiar, R | 1 |
| Frank, L | 1 |
| Margolis, MK | 1 |
| Vorsanger, G | 1 |
| Solassol, I | 1 |
| Bressolle, F | 1 |
| Caumette, L | 1 |
| Garcia, F | 1 |
| Poujol, S | 1 |
| Culine, S | 1 |
| Pinguet, F | 1 |
| Freynhagen, R | 1 |
| von Giesen, HJ | 1 |
| Busche, P | 1 |
| Sabatowski, R | 2 |
| Konrad, C | 1 |
| Grond, S | 1 |
| Allan, L | 2 |
| Finkel, JC | 1 |
| Finley, A | 1 |
| Greco, C | 1 |
| Weisman, SJ | 1 |
| Zeltzer, L | 1 |
| Naja, MZ | 1 |
| Al-Tannir, M | 1 |
| Naja, H | 1 |
| Ziade, MF | 1 |
| Zeidan, A | 1 |
| Kochs, E | 1 |
| Zimmermann, M | 2 |
| Manchikanti, L | 1 |
| Manchikanti, KN | 1 |
| Manchukonda, R | 1 |
| Pampati, V | 1 |
| Cash, KA | 1 |
| Waap, I | 1 |
| Otis, J | 1 |
| Rothman, M | 1 |
| Greiner, W | 1 |
| Lehmann, K | 1 |
| Earnshaw, S | 1 |
| Bug, C | 1 |
| Peppin, J | 1 |
| Taylor, DR | 1 |
| Webster, LR | 1 |
| Chun, SY | 1 |
| Reinking, J | 1 |
| Stegman, M | 1 |
| Shoemaker, S | 1 |
| Fortner, B | 1 |
| Simpson, DM | 1 |
| Hale, M | 1 |
| Friedrichsdorf, SJ | 1 |
| Kang, TI | 1 |
| Lu, YL | 1 |
| Wang, XD | 1 |
| Lai, RC | 1 |
| Darwish, M | 1 |
| Eipe, N | 1 |
| Kay, J | 1 |
| Markman, JD | 1 |
| Gourlay, GK | 2 |
| Cousins, MJ | 2 |
| Singler, RC | 1 |
| Colpaert, FC | 2 |
| Meert, T | 1 |
| De Witte, P | 1 |
| Schmitt, P | 1 |
| Laorden, ML | 1 |
| Miralles, F | 1 |
| Olaso, MJ | 1 |
| Puig, MM | 1 |
| Hiew, CY | 1 |
| Hart, GK | 1 |
| Thomson, KR | 1 |
| Hennessy, OF | 1 |
| Abidin, MR | 1 |
| Arosarena, O | 1 |
| Koch, WM | 1 |
| Eisele, DW | 1 |
| Bernstein, KJ | 1 |
| Estève, M | 1 |
| DeSio, JM | 1 |
| Bacon, DR | 1 |
| Peer, G | 1 |
| Lema, MJ | 1 |
| Anand, A | 1 |
| Carmosino, L | 1 |
| Glatt, AE | 1 |
| Patt, RB | 2 |
| Hogan, LA | 2 |
| Lehr, VT | 1 |
| Renaud, EA | 1 |
| Sylvester, RK | 1 |
| Levitt, R | 1 |
| Steen, PD | 1 |
| Shamilian, A | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Marquardt, KA | 1 |
| Tharratt, RS | 1 |
| Musallam, NA | 1 |
| Karadimov, D | 1 |
| Vasilev, D | 1 |
| Milanova, M | 1 |
| Pasero, CL | 2 |
| McCaffery, M | 2 |
| Simpson, RK | 1 |
| Edmondson, EA | 1 |
| Constant, CF | 1 |
| Collier, C | 1 |
| Bral, EE | 1 |
| Curtiss, CP | 1 |
| Sloan, PA | 1 |
| Moulin, DE | 1 |
| Hays, H | 2 |
| Wakefield, B | 1 |
| Johnson, JA | 1 |
| Kron-Chalupa, J | 1 |
| Paulsen, L | 1 |
| MacConnachie, AM | 1 |
| Tobias, JD | 1 |
| Józef Kucharz, E | 1 |
| Niemann, T | 1 |
| Madsen, LG | 1 |
| Larsen, S | 1 |
| Thorsgaard, N | 1 |
| Makin, MK | 1 |
| Newshan, G | 1 |
| Lefkowitz, M | 1 |
| Neighbors, DM | 1 |
| Bell, TJ | 1 |
| Wilson, J | 1 |
| Dodd, SL | 1 |
| Tarayre, JP | 1 |
| Alliaga, M | 1 |
| Bruins Slot, LA | 1 |
| Attal, N | 1 |
| Koek, W | 1 |
| Jensen, NH | 1 |
| de Waroux, BL | 1 |
| Bolt, M | 1 |
| Donald, R | 1 |
| Kalso, E | 1 |
| Dionne, RA | 1 |
| Lepinski, AM | 1 |
| Gordon, SM | 1 |
| Jaber, L | 1 |
| Brahim, JS | 1 |
| Hargreaves, KM | 1 |
| Dukes, EM | 1 |
| Dhanda, R | 1 |
| Oster, G | 1 |
| Matoba, M | 1 |
| Murakami, S | 1 |
| Hoka, S | 1 |
| Bleeker, CP | 1 |
| Bremer, RC | 1 |
| Dongelmans, DA | 1 |
| van Dongen, RT | 1 |
| Crul, BJ | 1 |
| Dellemijn, PL | 1 |
| Heidemann, AJ | 1 |
| Seaton, TL | 1 |
| Burgess, FW | 1 |
| Javier, FO | 1 |
| Magpantay, LA | 1 |
| Espinosa, EL | 1 |
| Harder, SM | 1 |
| Unite, MA | 1 |
| Kefalianakis, F | 1 |
| Kugler, M | 1 |
| van der Auwera, R | 1 |
| Kugler, G | 1 |
| Benítez Del Rosario, MA | 1 |
| Pérez Suárez, MC | 1 |
| Fernández Díaz, R | 1 |
| Cabrejas Sánchez, A | 1 |
| Yee, LY | 1 |
| Lopez, JR | 1 |
| Simmonds, MA | 1 |
| Richenbacher, J | 1 |
| Herbst, LH | 1 |
| Strause, LG | 1 |
| Baktai, G | 1 |
| Székely, E | 1 |
| Márialigeti, T | 1 |
| Kovács, L | 1 |
| Calis, KA | 1 |
| Kohler, DR | 1 |
| Corso, DM | 1 |
| Nightingale, SL | 1 |
| Liu, FY | 1 |
| Northrop, RB | 1 |
| Ellis, JS | 1 |
| Ramamurthy, S | 1 |
| Schoenfeld, LS | 1 |
| Hoffman, J | 1 |
| Walsh, NE | 1 |
| Miser, AW | 1 |
| Narang, PK | 1 |
| Dothage, JA | 1 |
| Young, RC | 1 |
| Sindelar, W | 1 |
| Miser, JS | 1 |
| Chabal, C | 1 |
| Jacobson, L | 1 |
| Little, J | 1 |
| Cherry, DA | 1 |
| McLachlan, M | 1 |
| Zverev, VV | 1 |
| Zeller, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Structural and Molecular Neuroplasticity in Migraine[NCT03004313] | 32 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| Morphine or Fentanyl for Refractory Dyspnea in COPD[NCT03834363] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-11-15 | Recruiting | ||
| Endogenous Opioid Systems and Symptom Change in Fibromyalgia[NCT02866461] | 0 participants (Actual) | Observational | 2021-11-30 | Withdrawn (stopped due to It was not possible to conduct this study at the University of Utah due to the inability of the PET research facility to synthesize the radiotracer central to this project. Project was transferred to another institution.) | |||
| The Role of Endogenous Opioids in Mindfulness-based Chronic Pain Relief[NCT04034004] | Early Phase 1 | 88 participants (Actual) | Interventional | 2021-01-01 | Completed | ||
| Evaluation in Efficacy and Safety of Fentanyl-TTS (Durogesic® D-Trans) for Treatment of Chronic Pain[NCT01902524] | Phase 4 | 65 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Comparative Study of Influence of Surgical Pleth Index Guided Total Intravenous Anaesthesia (TIVA) or Volatile Anaesthesia Using Sevoflurane or Desflurane on the Intraoperative Blood Loss During Functional Endoscopic Sinus Surgery[NCT03417180] | 120 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | |||
| Comparative Study of Influence of Total Intravenous Anaesthesia (TIVA) and Volatile Anaesthesia Using Sevoflurane or Desflurane on the Intraoperative Blood Loss During Functional Endoscopic Sinus Surgery[NCT03417206] | 120 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | |||
| Comparative Study of Influence of Different Techniques of Remifentanil Titration During Functional Endoscopic Sinus Surgery Under Total Intravenous Anaesthesia (TIVA)[NCT03389763] | 105 participants (Actual) | Interventional | 2016-06-01 | Completed | |||
| Assessing the Content Validity of a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation[NCT01645371] | 79 participants (Actual) | Observational | 2012-08-31 | Completed | |||
| Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre, Interventional Clinical Trial to Assess the Efficacy and Safety of the Food Supplement Microsmin® Plus in the Symptomatic Treatment of Haemorrhoids[NCT05750563] | 80 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| Bel-boyun ağrısı Nedeniyle başvuran Hastalarda farklı Fizyoterapi ve Manuel Terapi yöntemlerinin ağrı, Fonksiyon ve yaşam Kalitesi düzeyleri üzerin Etkisi[NCT02696057] | 113 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| A Study to Assess the Safety, Dose Conversion and Titration of DURAGESIC® (Fentanyl Transdermal System) in Pediatric Subjects With Chronic Pain Requiring Opioid Therapy[NCT00271466] | Phase 3 | 199 participants (Actual) | Interventional | 2000-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04034004)
Timeframe: Delivered after completion of each of the 4 meditation intervention sessions. Up to 8 weeks.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| intervention 1 effectiveness | intervention 2 effectiveness | intervention 3 effectiveness | intervention 4 effectiveness | |
| Mindfulness Meditation | 4.83 | 4.05 | 4.21 | 4.51 |
| Non-mindfulness Meditation | 5.13 | 5.17 | 5.21 | 5.40 |
Pain severity and interference: impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week. Higher scores indicate higher chronic pain. BPI severity and interference scales are used and collected before and after each intervention. Higher BPI severity indicate higher chronic pain severity. Higher BPI interference scores indicate higher chronic pain interference.The scoring scale for severity and interference range from 0 - 10, respectively. (NCT04034004)
Timeframe: Administered at the baseline, post-intervention session 6 and post-intervention session 7. Outcome measurements will compare in BPI severity and interference from baseline to session 7.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| baseline BPI severity | session 7 BPI severity | baseline BPI interference | session 7 BPI interference | |
| Mindfulness Meditation | 4.47 | 3.94 | 4.40 | 3.38 |
| Non-mindfulness Meditation | 5.22 | 5.15 | 5.17 | 4.57 |
This is a 13-item questionnaire with 3 subscales assessing rumination, magnification, and helplessness in patients. A numeric value between 0 (not at all) and 4 (all the time) is provided in response to each statement. Scores on this assessment range from 0 to 52, with higher values reflecting more salient impacts of pain on one's day to day experience. The total range is from 0 - 52. (NCT04034004)
Timeframe: The Pain Catastrophizing Scale was administered at the baseline, post-intervention session 6 and session 7. Outcome measurements will compare change in Pain Catastrophizing Scale from baseline to session 7.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline PCS | Session 7 PCS | |
| Mindfulness Meditation | 18.57 | 15.33 |
| Non-mindfulness Meditation | 20.83 | 18.48 |
"Numerical pain ratings (NRS) will be assessed while lying on the back and in response to the straight leg raise test (SLR). Pain ratings will be collected during SLR 1 and SLR 2 in the baseline, saline and naloxone sessions, respectively. The 11 point scan will include a minimum rating of 0 which is characterized as no pain whereas the maximum (10) is labeled as most intense imaginable. Higher numbers correspond to higher pain." (NCT04034004)
Timeframe: Pain ratings were collected while lying supine and in response to the straight leg raise test. Collected twice, once in the first half and one in the second half of the baseline, saline infusion and naloxone infusion sessions. Up to 8 weeks total.
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| baseline session: supine 1 | baseline session: straight leg raise test 1 | baseline session: supine 2 | baseline session: straight leg raise test 2 | saline session: supine 1 | saline session: straight leg raise test 1 | saline session: supine 2 | saline session: straight leg raise 2 | naloxone session: supine 1 | naloxone session: straight leg raise 1 | naloxone session: supine 2 | naloxone session: straight leg raise 2 | |
| Mindfulness Meditation | 3.60 | 4.83 | 4.13 | 5.15 | 3.23 | 4.37 | 3.90 | 3.67 | 3.30 | 4.30 | 3.73 | 3.45 |
| Non Mindfulness Meditation | 4.69 | 5.41 | 4.76 | 5.78 | 4.62 | 5.75 | 4.37 | 5.32 | 4.82 | 6.10 | 5.18 | 5.52 |
This is a 12-item version of the SF-12 item Health Survey designed to assess general mental and physical functioning, and overall health-related quality of life. We used the physical functioning SF-12 scale and collected this information before and after each intervention and by group. The total range of scores is from 0 - 100. The minimum total score is 0 and the maximum score is 100. Higher scores indicate better functioning. (NCT04034004)
Timeframe: Up to 8 weeks. Administered at visit 1, 6 and 7. Outcome measurements will compare SF-12 health survey from baseline to session 7.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| baseline SF physical functioning | session 7 SF physical functioning | |
| Mindfulness Meditation | 52.50 | 39.66 |
| Non-mindfulness Meditation | 49.17 | 44.83 |
The Roland-Morris Questionnaire (RMDQ) is a self-administered disability measure in which greater levels of disability are reflected by higher numbers on a 24-point scale. The RMDQ has been shown to yield reliable measurements, which are valid for inferring the level of disability, and to be sensitive to change over time for groups of patients with low back pain. Higher scores indicate greater disability. Total RMDQ scores are used before and after each intervention by group. The range of scores is from 0 - 24. (NCT04034004)
Timeframe: The Roland-Morris Disability Questionnaire was administered at the baseline, post-intervention session 6 and session 7. Outcome measurements will compare RMDQ from baseline to session 7.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| baseline RMDQ | session 7 RMDQ | |
| Mindfulness Meditation | 12.86 | 12.03 |
| Non-mindfulness Meditation | 13.85 | 14.02 |
26 reviews available for fentanyl and Chronic Disease
| Article | Year |
|---|---|
Drug-Induced Cough.
Topics: Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Chr | 2020 |
Fentanyl for the relief of refractory breathlessness: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Drug-Related Side E | 2013 |
Pharmacotherapeutic management of breakthrough pain in patients with chronic persistent pain.
Topics: Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Pain | 2008 |
Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain, I | 2008 |
[Generics in pain therapy].
Topics: Administration, Cutaneous; Administration, Oral; Aged; Analgesics, Opioid; Chronic Disease; Drugs, G | 2008 |
[Difference in tolerance to anti-hyperalgesic effect and its molecular mechanisms between chronic treatment with morphine, fentanyl and oxycodone in a chronic pain-like state].
Topics: Analgesics, Opioid; Animals; beta-Endorphin; Chronic Disease; Disease Models, Animal; Drug Tolerance | 2008 |
The role of transdermal fentanyl patches in the effective management of cancer pain.
Topics: Acute Disease; Administration, Cutaneous; Analgesics, Opioid; Chemistry, Pharmaceutical; Chronic Dis | 2009 |
Transdermal fentanyl: pharmacology and toxicology.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Drug Carriers; Drug Overdose; Fentan | 2009 |
Fentanyl patches: preventable overdose.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Drug Overdose; Fentanyl; Humans; Pai | 2010 |
Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
Topics: Administration, Buccal; Algorithms; Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; D | 2010 |
[Breakthrough pain--what to consider when treating with rapid onset opioids].
Topics: Administration, Intranasal; Administration, Oral; Administration, Sublingual; Algorithms; Chronic Di | 2011 |
Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Body Weight; Chronic Disease; Female; Fentanyl; Human | 2003 |
Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2004 |
Cancer pain management in children.
Topics: Analgesics, Opioid; Anesthesia, Conduction; Child; Chronic Disease; Fentanyl; Humans; Injections, Sp | 2004 |
The management of pain in children with life-limiting illnesses.
Topics: Analgesics, Opioid; Child; Chronic Disease; Codeine; Fentanyl; Humans; Hydromorphone; Ketamine; Meth | 2007 |
Fentanyl buccal tablet.
Topics: Administration, Buccal; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain; Pain | 2008 |
[Transcutaneous fentanyl].
Topics: Administration, Cutaneous; Chronic Disease; Fentanyl; Humans; Pain, Intractable; Pain, Postoperative | 1994 |
Comment: transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Neopl | 1993 |
Fentanyl in the treatment of cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Biological Availability; Chronic Disease; Fentanyl; | 1997 |
Caring for adults with chronic cancer pain.
Topics: Adult; Analgesics; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Neoplasms; Oncolog | 1998 |
Analgesics in the management of chronic pain. Part five: Step 3 parenteral analgesic drug therapy.
Topics: Administration, Cutaneous; Analgesics; Chronic Disease; Fentanyl; Heroin; Humans; Infusions, Parente | 1999 |
Strong opioids for cancer pain.
Topics: Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Morphine; Neoplasms; Neurotoxicity Syndromes; | 2001 |
[Issues in cancer pain management].
Topics: Analgesics, Opioid; Chronic Disease; Clinical Protocols; Fentanyl; Home Care Services; Humans; Morph | 2001 |
Transdermal fentanyl.
Topics: Administration, Cutaneous; Aged; Chemistry, Pharmaceutical; Chronic Disease; Clinical Trials as Topi | 1992 |
Transdermal fentanyl: long-term analgesic studies.
Topics: Administration, Cutaneous; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Neoplasms; P | 1992 |
Transdermally administered fentanyl for pain management.
Topics: Administration, Cutaneous; Animals; Chronic Disease; Contraindications; Fentanyl; Humans; Neoplasms; | 1992 |
41 trials available for fentanyl and Chronic Disease
| Article | Year |
|---|---|
Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system.
Topics: Adult; Amygdala; Analgesics, Opioid; Caudate Nucleus; Chronic Disease; Female; Fentanyl; Humans; Mal | 2019 |
[Breakthrough pain treatment with sublingual fentanyl in patients with chronic cutaneous ulcers].
Topics: Administration, Sublingual; Aged; Chronic Disease; Constipation; Female; Fentanyl; Humans; Male; Mid | 2014 |
Acute opioid administration improves work-related exercise performance in patients with chronic back pain.
Topics: Adult; Analgesics, Opioid; Back Pain; Chronic Disease; Cross-Over Studies; Double-Blind Method; Exer | 2008 |
[Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Delayed-Action Preparations; Female; | 2008 |
Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
Topics: Administration, Buccal; Analgesics, Opioid; Chronic Disease; Disease Progression; Drug Tolerance; Fe | 2009 |
Opioids switching with transdermal systems in chronic cancer pain.
Topics: Adult; Aged; Analgesia; Analgesics, Opioid; Buprenorphine; Chronic Disease; Female; Fentanyl; Humans | 2009 |
Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Chronic Disease; Double-Blind Method; Female; F | 2011 |
Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study.
Topics: Administration, Buccal; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Dise | 2010 |
A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain.
Topics: Administration, Buccal; Adult; Analgesics, Opioid; Chronic Disease; Cross-Over Studies; Double-Blind | 2010 |
Evaluation of efficacy and safety of fentanyl transdermal patch (Durogesic D-TRANS) in chronic pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Male; | 2011 |
The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain.
Topics: Administration, Buccal; Adult; Analgesics, Opioid; Chronic Disease; Cross-Over Studies; Disease Mana | 2011 |
Transdermal fentanyl for chronic low back pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Fentanyl; Humans | 2012 |
A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Disease; Chronic Pain; | 2013 |
The effect of opioid analgesia on exercise test performance in chronic low back pain.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Disease; Cross-Over Studies; Exercise; Exercise Test; Femal | 2003 |
Self-treatment with oral transmucosal fentanyl citrate to prevent emergency room visits for pain crises: patient self-reports of efficacy and utility.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; California; Chronic Disease; Emergency | 2002 |
Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain.
Topics: Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administra | 2004 |
The effect of transdermal fentanyl treatment on serum cortisol concentrations in patients with non-cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Hyd | 2004 |
Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Delayed-Action Preparations; Fentany | 2004 |
Comparison of propofol and sevoflurane anesthesia by means of blood loss during endoscopic sinus surgery.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Ane | 2004 |
Comparison of propofol and sevoflurane anesthesia by means of blood loss during endoscopic sinus surgery.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Ane | 2004 |
Comparison of propofol and sevoflurane anesthesia by means of blood loss during endoscopic sinus surgery.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Ane | 2004 |
Comparison of propofol and sevoflurane anesthesia by means of blood loss during endoscopic sinus surgery.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Ane | 2004 |
Comparison of propofol and sevoflurane anesthesia by means of blood loss during endoscopic sinus surgery.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Ane | 2004 |
Comparison of propofol and sevoflurane anesthesia by means of blood loss during endoscopic sinus surgery.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Ane | 2004 |
Comparison of propofol and sevoflurane anesthesia by means of blood loss during endoscopic sinus surgery.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Ane | 2004 |
Comparison of propofol and sevoflurane anesthesia by means of blood loss during endoscopic sinus surgery.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Ane | 2004 |
Comparison of propofol and sevoflurane anesthesia by means of blood loss during endoscopic sinus surgery.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Ane | 2004 |
[The use of transdermal fentanyl in chronic non-malignant pain].
Topics: Activities of Daily Living; Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Female; | 2005 |
Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2006 |
Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2006 |
Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2006 |
Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2006 |
Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
Topics: Acetaminophen; Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; | 2005 |
Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Male | 2005 |
Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Chronic Disease; Constipation; | 2005 |
Transdermal fentanyl in the management of children with chronic severe pain: results from an international study.
Topics: Administration, Cutaneous; Adolescent; Analgesics, Opioid; Child; Child, Preschool; Chronic Disease; | 2005 |
Evaluation of therapeutic thoracic medial branch block effectiveness in chronic thoracic pain: a prospective outcome study with minimum 1-year follow up.
Topics: Adult; Back Pain; Chronic Disease; Disability Evaluation; Employment; Female; Fentanyl; Follow-Up St | 2006 |
[Individual aspects of the quality of life of patients with chronic pain. Observational study of treatment with fentanyl-TTS].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Child; Ch | 2005 |
A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic D | 2006 |
Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
Topics: Administration, Buccal; Adult; Analgesics, Opioid; Analysis of Variance; Chronic Disease; Disability | 2007 |
Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ).
Topics: Adult; Affect; Aged; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Male; Middle Age | 2007 |
Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Administration, Buccal; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Double-Blind M | 2007 |
[Correlation of acute pain treatment to occurrence of chronic pain in tumor patients after thoracotomy].
Topics: Acute Disease; Amides; Chronic Disease; Female; Fentanyl; Humans; Male; Middle Aged; Morphine; Pain, | 2008 |
Transdermal fentanyl as treatment for chronic low back pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Human | 1997 |
A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Evaluation | 1998 |
Opioid treatment of painful chronic pancreatitis.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Chronic Disease; Cross-Over Studies; Del | 2000 |
Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Cros | 2001 |
Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation.
Topics: Acute Disease; Adult; Analgesics, Opioid; Chronic Disease; Dose-Response Relationship, Drug; Double- | 2001 |
Opioids in non-cancer pain: a life-time sentence?
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Chronic Disease; Diabetic Neuropathies; | 2001 |
Transdermal fentanyl for chronic cancer pain: detailed case reports and the influence of confounding factors.
Topics: Administration, Cutaneous; Aged; Chronic Disease; Confounding Factors, Epidemiologic; Female; Fentan | 1992 |
Transdermal fentanyl use in hospice home-care patients with chronic cancer pain.
Topics: Administration, Cutaneous; Aged; Chronic Disease; Female; Fentanyl; Home Care Services; Hospices; Hu | 1992 |
Use of midazolam ('Dormicum') and flumazenil ('Anexate') in paediatric bronchology.
Topics: Anesthesia; Atropine; Bronchoscopy; Child, Preschool; Chronic Disease; Drug Administration Schedule; | 1992 |
84 other studies available for fentanyl and Chronic Disease
| Article | Year |
|---|---|
Alterations in endogenous opioid functional measures in chronic back pain.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Back Pain; Brain; Brain Mapping; Carbon Radioisotop | 2013 |
Alterations in endogenous opioid functional measures in chronic back pain.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Back Pain; Brain; Brain Mapping; Carbon Radioisotop | 2013 |
Alterations in endogenous opioid functional measures in chronic back pain.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Back Pain; Brain; Brain Mapping; Carbon Radioisotop | 2013 |
Alterations in endogenous opioid functional measures in chronic back pain.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Back Pain; Brain; Brain Mapping; Carbon Radioisotop | 2013 |
Chronic Back Pain Is Associated with Alterations in Dopamine Neurotransmission in the Ventral Striatum.
Topics: Adult; Analgesics, Opioid; Back Pain; Brain Mapping; Carbon Radioisotopes; Chronic Disease; Dopamine | 2015 |
Fentanyl patch for stable chronic pain in children: new indication. Used fentanyl patches should be handled with care.
Topics: Administration, Cutaneous; Adolescent; Analgesics, Opioid; Child; Child, Preschool; Chronic Disease; | 2008 |
Fentanyl transdermal analgesia during pregnancy and lactation.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Chronic Disease; Drug Residues; Female; Fentan | 2009 |
Long-term pain vulnerability after surgery in rats: prevention by nefopam, an analgesic with antihyperalgesic properties.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Carrageenan; Chronic Disease; Fentanyl; Hyper | 2009 |
The epidural works, but the patient hurts! Acute pain management of the chronic pain patient.
Topics: Acute Disease; Analgesia, Epidural; Analgesics, Opioid; Chronic Disease; Continuity of Patient Care; | 2009 |
[Fentanyl patch in the treatment of severe chronic pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Delayed-Ac | 2009 |
Formulations of fentanyl for the management of pain.
Topics: Administration, Buccal; Administration, Cutaneous; Administration, Oral; Analgesia, Patient-Controll | 2010 |
Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Dose | 2010 |
[Analgesic efficacy and tolerability of a generic fentanyl patch (TTS). Results of two post-marketing surveillance studies including 850 patients].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Analgesics, Opioid; Chronic Disease; Dose-Respon | 2009 |
Mechanically strong geopolymers offer new possibilities in treatment of chronic pain.
Topics: Analgesics, Opioid; Chronic Disease; Compressive Strength; Delayed-Action Preparations; Fentanyl; Hu | 2010 |
Case scenario: self-extraction of intrathecal pump medication with a concomitant intrathecal granulomatous mass.
Topics: Acetaminophen; Administration, Cutaneous; Adult; Analgesics; Analgesics, Non-Narcotic; Analgesics, O | 2011 |
Chronic psychosocial stress induces visceral hyperalgesia in mice.
Topics: Adrenal Glands; Analgesics, Opioid; Animals; Anxiety; Atropine; Body Weight; Chronic Disease; Colon; | 2012 |
I just started using a fentanyl patch for chronic back pain. What special precautions should I take?
Topics: Administration, Cutaneous; Analgesics, Opioid; Back Pain; Chronic Disease; Fentanyl; Humans; Patient | 2012 |
[Pain therapy. Exaggerated anxiety regarding opioid administration].
Topics: Administration, Cutaneous; Analgesics, Opioid; Anxiety; Chronic Disease; Fentanyl; Humans; Pain | 2002 |
[Treatment of pain with opioid analgesics and the role of TTS-fentanyl (Durogesic)].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Pain | 2001 |
[Treatment of chronic pain--use of transdermal fentanyl (Durogesic TTS)].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Female; Fen | 2002 |
Transdermal fentanyl: informed prescribing is essential.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Dose-Respon | 2003 |
Chronic pain syndrome after laparoscopic radical nephrectomy.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Carcinoma, Renal Cell; Carcinoma, Transition | 2003 |
The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Automobile Driving; Chronic Disease; Cognition; | 2004 |
Evaluation of safety and efficacy of transdermal therapeutic system-fentanyl in adult patients with gynecological cancer-related pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Chronic Disease; Drug Delivery Systems; Fema | 2004 |
A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Cancer Care Facilities; Chronic Disease; | 2004 |
Anaesthesia for Homans' procedure.
Topics: Analgesics, Opioid; Anesthesia, General; Anesthetics, Intravenous; Chronic Disease; Dermatologic Sur | 2004 |
Oral transmucosal abuse of transdermal fentanyl.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Chronic Disease; Depressive Disorder; Drug A | 2004 |
[Monitoring of blood pressure during phacotrabeculectomy].
Topics: Aged; Aged, 80 and over; Anesthetics, Intravenous; Blood Pressure; Blood Pressure Determination; Car | 2004 |
[Chronic pain--new patch size expands therapy spectrum].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; | 2004 |
[Paradigm change in therapy of moderate chronic opioid responsive pain. Fentanyl alternative to weak opioids].
Topics: Administration, Cutaneous; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chronic Dise | 2004 |
Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chroni | 2005 |
Principles of pain management: agents used for somatic pain.
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chronic | 2005 |
[Clinical trials: early use of transdermal opioid therapy].
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Antirheumatic Agents; Arthritis; Chronic Disea | 2005 |
An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Data | 2005 |
[Effective pain therapy with good tolerability. New opioid administration form by transdermal patch].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; | 2005 |
[Reliably pain free with a new fentanyl patch].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Pain | 2005 |
[Simple to use--superior adhesiveness].
Topics: Adhesiveness; Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Pain | 2005 |
Repeated nerve blocks with clonidine, fentanyl and bupivacaine for trigeminal neuralgia.
Topics: Anesthetics; Bupivacaine; Chronic Disease; Clonidine; Electric Stimulation; Fentanyl; Humans; Nerve | 2006 |
[Pain: etiology and drug treatment].
Topics: Acute Disease; Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Noc | 2005 |
[Medico-legal aspects of the use of fentanyl patches].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Drug Overdose; Fentanyl; Germany; Hu | 2006 |
Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Chronic Disease; Cost-Benefit Analysis | 2006 |
Spontaneously breathing technique for opioid tolerance.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Anesthetics, Inhalation; Anti-Inflammatory | 2008 |
Not so fast: the reformulation of fentanyl and breakthrough chronic non-cancer pain.
Topics: Analgesics, Opioid; Chronic Disease; Drug Approval; Fentanyl; Humans; Neoplasms; Opioid-Related Diso | 2008 |
Strong analgesics in severe pain.
Topics: Analgesics, Opioid; Chronic Disease; Cocaine; Fentanyl; Half-Life; Heroin; Humans; Injections, Intra | 1984 |
An improved technique for alcohol neurolysis of the celiac plexus.
Topics: Abdominal Neoplasms; Anesthesia, Local; Celiac Plexus; Chronic Disease; Crohn Disease; Denervation; | 1982 |
Further evidence validating adjuvant arthritis as an experimental model of chronic pain in the rat.
Topics: Animals; Arthritis; Arthritis, Experimental; Body Weight; Chronic Disease; Disease Models, Animal; D | 1982 |
[Measurement of endorphins in human cerebrospinal fluid. Comparative study of various groups of patients].
Topics: Adult; Aged; Anesthetics; Animals; Biological Assay; Chronic Disease; Droperidol; Endorphins; Female | 1982 |
Analgesia and sedation in interventional radiological procedures.
Topics: Aged; Ambulatory Care; Analgesia; Analgesics; Analgesics, Opioid; Anesthesia, General; Anesthetics, | 1995 |
Transdermal fentanyl.
Topics: Administration, Cutaneous; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain | 1994 |
Inappropriate use of transdermal fentanyl for acute postoperative pain.
Topics: Acute Disease; Administration, Cutaneous; Chronic Disease; Contraindications; Fentanyl; Humans; Hypo | 1994 |
Intravenous abuse of transdermal fentanyl therapy in a chronic pain patient.
Topics: Administration, Cutaneous; Adult; Chronic Disease; Female; Fentanyl; Humans; Pain; Substance Abuse, | 1993 |
Evaluation of recalcitrant pain in HIV-infected hospitalized patients.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Chronic Disease; Female; Fentanyl; HIV Infec | 1994 |
High transdermal fentanyl requirements in a patient with chronic cancer pain.
Topics: Administration, Cutaneous; Adult; Carcinoma, Squamous Cell; Chronic Disease; Female; Fentanyl; Human | 1993 |
Opioid-induced muscle activity: implications for managing chronic pain.
Topics: Adenocarcinoma, Mucinous; Aged; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Hyperkinesis; | 1995 |
Drug-use evaluation of transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Drug Utilization Review; Fentanyl; H | 1995 |
Using high-dose fentanyl patches.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Lung Neoplasms; Ma | 1996 |
Fentanyl remaining in a transdermal system following three days of continuous use.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Medical Waste Disp | 1995 |
[Diprivan anesthesia in a case with intraoperative corticography].
Topics: Adolescent; Anesthesia, Intravenous; Anesthetics, Combined; Anesthetics, Intravenous; Cerebral Corte | 1996 |
Transdermal fentanyl for chronic pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Morphine; Neoplasm | 1997 |
Breakthrough pain with the fentanyl patch.
Topics: Administration, Oral; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain; Salvag | 1997 |
Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain; Q | 1998 |
Chronic cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Neo | 1998 |
A research-based guideline for appropriate use of transdermal fentanyl to treat chronic pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Drug Costs; Evidence-Based Medicine; | 1998 |
[Transdermal Phentanyl. New therapeutic option in chronic non-tumor-induced pain].
Topics: Analgesics, Opioid; Chronic Disease; Drug Therapy, Combination; Fentanyl; Humans; Morphine; Pain | 1999 |
Applications of intrathecal catheters in children.
Topics: Adenocarcinoma; Adolescent; Analgesia, Epidural; Analgesics, Opioid; Anesthesia, Spinal; Anesthetics | 2000 |
Transdermal fentanyl: new preparation. An alternative to morphine.
Topics: Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Morphine; Neoplasms | 1998 |
[Conference: opioids in the treatment of chronic pain: moving into the future with Durogestic, Valencia, November 19-20, 1999].
Topics: Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Pain | 1999 |
Transdermal fentanyl for chronic pain in AIDS: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Administration, Cutaneous; Adult; Analgesics, Opioid; Chronic Di | 2001 |
Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Health Care Costs; Humans; | 2001 |
Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats.
Topics: Analgesics, Opioid; Animals; Arthritis; Behavior, Animal; Chronic Disease; Fentanyl; Male; Naloxone; | 2001 |
Re: Economic evaluation of the fentanyl transdermal system.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Cost-Benefit Analysis; Fentanyl; Hum | 2001 |
Re: Economic evaluation of fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Cost-Benefit Analysis; Fentanyl; Hum | 2001 |
Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report.
Topics: Administration, Cutaneous; Analgesia, Epidural; Analgesics, Opioid; Anesthetics, Local; Breast Neopl | 2001 |
Do patients prefer transdermal fentanyl or sustained-release oral morphine for treatment of chronic non-cancer pain?
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2001 |
Opioid therapy for chronic painful conditions.
Topics: Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Karnofsky Performan | 2001 |
Opioid use in chronic pain management in the Philippines.
Topics: Analgesics, Opioid; Chronic Disease; Fentanyl; Health Knowledge, Attitudes, Practice; Humans; Meperi | 2001 |
[Opioid rotation in pain therapy. Case report].
Topics: Administration, Cutaneous; Chronic Disease; Fentanyl; Humans; Hydromorphone; Injections, Subcutaneou | 2002 |
[Paliative treatment: Treatment of chronic cancer pain (ii): the use of opiates].
Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Analgesics, O | 2002 |
[Staged pain therapy plan. Opioid patch for chronic pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Dose-Response Relationship, Drug; Fe | 2002 |
From the Food and Drug Administration.
Topics: Chronic Disease; Diet Fads; Dietary Fiber; Drug Combinations; Esophageal Stenosis; Fatty Alcohols; F | 1990 |
A new approach to the modeling and control of postoperative pain.
Topics: Analgesia, Patient-Controlled; Chronic Disease; Computer Simulation; Fentanyl; Humans; Injections, I | 1990 |
Diagnostic epidural opioid technique.
Topics: Adult; Age Factors; Aged; Analgesia, Epidural; Chronic Disease; Disability Evaluation; Female; Fenta | 1989 |
Transdermal fentanyl for pain control in patients with cancer.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chronic Disease; Female; Fentanyl; Humans; Male; | 1989 |
Intrathecal fentanyl depresses nociceptive flexion reflexes in patients with chronic pain.
Topics: Aged; Chronic Disease; Depression, Chemical; Fentanyl; Humans; Injections, Spinal; Middle Aged; Noci | 1989 |
Diagnostic epidural opioid blockade and chronic pain: preliminary report.
Topics: Adult; Aged; Anesthesia, Epidural; Back Pain; Chronic Disease; Diagnosis, Differential; Female; Fent | 1985 |
[Clinico-physiological substantiation of using various methods of anesthesia in operations on the lungs in patients with chronic respiratory insufficiency].
Topics: Anesthesia, General; Chronic Disease; Ether; Fentanyl; Halothane; Hemodynamics; Humans; Lung Disease | 1985 |
[Anesthesia in chronic patients].
Topics: Adult; Aged; Anesthesia; Anesthetics; Anti-Bacterial Agents; Asthma; Benperidol; Chronic Disease; Fe | 1969 |